%0 Case Reports
%T A case report and literature review on tocilizumab-cured acute necrotizing encephalopathy caused by influenza A virus.
%A Huang Y
%A Zhou B
%A Hong S
%A Cai Y
%J Front Pediatr
%V 12
%N 0
%D 2024
%M 38646514
%F 3.569
%R 10.3389/fped.2024.1351478
%X <B>UNASSIGNED: </B>Acute Necrotizing Encephalopathy (ANE), is a kind of severe Central Nervous System Disease. The commonest pathogen is the influenza virus. The pathogenesis of ANE is bound up to genetic susceptibility and cytokine storm. Interleukin-6 (IL-6) is deemed as the core function in cytokine storm of ANE and that plays a significant role in evaluating the severity of Influenza-Related ANE. Tocilizumab, an IL-6 antagonist, is known to be safe and effective in the treatment of ANE when used early and has an essential role in improving prognosis and preventing disability.<BR><B>UNASSIGNED: </B>This case reports a 2 year 10 month old boy who developed ANE after being infected with influenza A virus (H1N1-2019). After treatment with Tocilizumab, the child's consciousness was clear, no convulsions occurred, the movement of limbs was improved, and the lesions of encephalopathy were significantly reduced.<BR><B>UNASSIGNED: </B>The early use of Tocilizumab is safe and effective for the treatment of ANE caused by influenza virus.